

بسم الله الرحمن الرحيم



HOSSAM MAGHRABY



شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



HOSSAM MAGHRABY

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HOSSAM MAGHRABY



Ain Shams University
Faculty of Pharmacy

Evaluating the efficacy and safety of Sorafenib versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients

A Thesis

Submitted in Fulfillment of the Requirements for the

Philosophy degree

In Pharmaceutical Sciences

(Clinical Pharmacy)

By

Noha Salah El Din Mohamed El Baghdady

Master of Pharmaceutical sciences, 2013

Lecturer assistant, Clinical Pharmacy Department

School of Pharmacy, New Giza University

2021



Evaluating the efficacy and safety of Sorafenib versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients

A Thesis

Submitted in Fulfillment of the Requirements for the

Philosophy degree

In Pharmaceutical Sciences (**Clinical Pharmacy**)

By

Noha Salah EL Din Mohamed El Baghdady

Assistant Lecturer, Clinical Pharmacy Department

Faculty of Pharmacy, New Giza University

Under Supervision of

Dr. Lamia Mohamed EL Wakeel, PhD

Professor of Clinical Pharmacy,
Faculty of Pharmacy, Ain Shams University

Dr. Abdel Rahman Mohamed El Naggar, MD

Professor of Clinical Pharmacology,
Faculty of Medicine, Cairo University

Dr. Mahmoud Abbass Ellithy, MD

Professor of Medical Oncology,
Faculty of Medicine, Ain-Shams University

Dr. Sara Mahmoud Zaki Shahin, PhD.

Associate Professor of Clinical Pharmacy,
Faculty of Pharmacy, Ain Shams University

2021

Acknowledgments

First, I thank "**Allah**" for granting me the power to accomplish this work.

I would like to express my deepest thanks to **Prof. Dr. El Wakeel**, Professor of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, for her valuable scientific guidance, constructive advices, and incessant supervision throughout the work. Her constructive criticism guided me immensely throughout the work and during the revision.

My deepest gratitude and indebtedness are expressed to **Prof. Dr. El Naggat**, the Professor of Clinical Pharmacology, Faculty of Medicine, Cairo University. for his deific support. Dr. Abdel Rahman no longer with us. I ask ALLAH to elevate his station among those who are guided.

I am also greatly obliged to **Dr. Ellithy**, Professor of Medical Oncology, Faculty of Medicine, Ain Shams University, for suggesting the topic of research and for providing continuous scientific supervision and follow up.

I am also greatly grateful to **Dr. Zaki**, Associate Professor of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University for her valuable time and effort are greatly appreciated.

My deepest gratitude to **Dr. Nawal EL Tohamy**, head of Medical Oncology Department, Electricity hospital. And, **Dr. Abeer Abdalla Mahmoud**, Medical oncology consultant, Electricity hospital, who have supported me throughout the entire process and without their support, this work would not be achieved.

Finally, my deepest everlasting thanks and appreciation are for my beloved parents, sister and brother for their continuous, endless love, prayers, support, and encouragement throughout my life.

والحمد لله رب العالمين.....

Noha Elbaghdady

Table of Contents

LIST OF ABBREVIATIONS	I
LIST OF FIGURES	VI
LIST OF TABLES	V
ABSTRACT	1
INTRODUCTION	2
LITERATURE REVIEW	4
A. Malignant Diseases	4
B. Liver cancer	5
C. Sorafenib	26
AIM OF THE STUDY	32
PATIENTS AND METHODS	33
RESULTS	49
DISCUSSION	72
CONCLUSION	77
SUMMARY	80
REFERENCES	83

الملخص العربي

List of Abbreviations

ADEs	Adverse Drug Events
AFP	Alpha Fetoprotein
AFP-L3	culinaris agglutinin-reactive Alpha Fetoprotein
BCLC	Barcelona Clinic Liver Cancer
BMI	Body Mass Index
BSC	Best Supportive Care
CA 19-9	Cancer Antigen19-9
CCA	Cholangiocarcinoma
CEA	Carcinoembryonic Antigen
CI	Confidence Interval
CLD	chronic Liver Disease
CT	Computed Tomography
CYP 450	Cytochrome p450
DAA	Direct Acting Antivirus
DCCA	Distal Cholangiocarcinoma
DCP	Des-gamma-Carboxy Prothrombin
EASL	The European Association for the Study of the Liver
ECOG	Eastern Cooperative Oncology Group Performance Status
EFS	Event-Free Survival
FACT-FHSI 8	Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 8

List of Abbreviations

G4	Genotype 4
HBV	Hepatitis B Virus
HFSR	Hand and Foot Skin Reaction
HCV	Hepatitis C Virus
HCC	Hepatocellular Carcinoma
HR	Hazard Ratios
HR	Hazard Ratio
iCCA	Intrahepatic Cholangiocarcinoma
ICER	Incremental Cost-Effectiveness Ratio
MAPK	Mitogen-Activated Protein kinase
mOS	median Overall Survival
mRECIST	Modified Response Evaluation Criteria in Solid Tumors
MRI	Magnetic Resonance Imaging
NAFLD	Nonalcoholic Fatty Liver Disease
NCCN	National Comprehensive Cancer Network
NCI-CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
OR	Odds Ratio
OS	Overall Survival
pCCA	Perihilar Cholangiocarcinoma
PDGFR	Platelet-Derived Growth Factor Receptor
PFS	Progression Free Survival
Qol	Quality of Life

List of Abbreviations

RAF	Radiofrequency
TACE	Trans-Arterial Chemoembolization
TKI	Tyrosine Kinase Inhibitor
US	Ultrasound
VEGFR	Vascular Endothelial Growth Factor Receptor

